• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Products
    • Products
      • Our Products & Technologies
      • hRPCs for Retinal Disease
      • CTX cells for Stroke Disability
      • ReNcell Products
      • Publications
    • Clinical Trials
      • Clinical Trials
      • Phase 1/2a clinical trial in retinitis pigmentosa
      • Phase 2b Clinical trial in stroke disability (PISCES III)
      • Phase 2a clinical trial in stroke disability (PISCES-II)
      • Phase 1 clinical trial in stroke disability (PISCES)
      • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Products
    • Products
      • Our Products & Technologies
      • hRPCs for Retinal Disease
      • CTX cells for Stroke Disability
      • ReNcell Products
      • Publications
    • Clinical Trials
      • Clinical Trials
      • Phase 1/2a clinical trial in retinitis pigmentosa
      • Phase 2b Clinical trial in stroke disability (PISCES III)
      • Phase 2a clinical trial in stroke disability (PISCES-II)
      • Phase 1 clinical trial in stroke disability (PISCES)
      • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Pioneering stem cell based exosome technologies

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company. Its primary objective is the development of novel stem cell based technologies targeting areas of significant unmet or poorly met medical need.

Learn More About our Award

Learn More About ReNeuron

Latest News

View all

Directorate Change – Catherine Isted appointed as Chief Executive Officer

Preliminary Results for the year ended 31 March 2022

Update on the Technology Transfer and Supply Agreement with Fosun Pharma

Notice of Results – Analyst meeting and Investor presentation

ReNeuron to present at International Society of Cell and Gene Therapy

Share Price

More details

26p 0.000p

at 14-08-2022 5:07:00

15 minute delayed share price from London Stock Exchange provided by Euroland.

Share Price

More details

26p 0.000p

at 14-08-2022 5:07:00

15 minute delayed share price from London Stock Exchange provided by Euroland.

Exosomes

Exosomes banner image Read more

iPSC

CTX cells for Critical Limb Ischaemia Read more

Investor Centre

Investor Centre banner image Read more

Subscribe here for our Press Releases:

The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: 

© ReNeuron Group plc 2022 All rights reserved

Website design by Carr Kamasa Design

  • Privacy Notice
  • Disclaimer